We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
bit.bio Logo

bit.bio

bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.

Latest bit.bio Content

Developing Next-Generation <i>In Vitro</i> Phenotypic Assays for Huntington’s Disease content piece image
App Note / Case Study

Developing Next-Generation In Vitro Phenotypic Assays for Huntington’s Disease

There is currently no effective cure or treatment to slow down or stop the progression of Huntington's disease (HD). One reason for this is the lack of accurate and easy-to-use HD models.
Alzheimer's Disease Pathogenesis: Emerging Role of Microglia content piece image
Webinar

Alzheimer's Disease Pathogenesis: Emerging Role of Microglia

On-Demand
Alzheimer’s disease is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer’s disease.
ioMicroglia™ – consistent iPSC-derived microglia, ready in 10 days! content piece image
Product
Advertisement

ioMicroglia™ – Consistent iPSC-Derived Microglia, Ready in 10 Days!

Discover ioMicroglia from bit.bio – human iPSC-derived microglia that are consistent, co-culture compatible and ready for experimentation in just 10 days. Limited early access vials are available now. Register your interest today.
bit.bio Adds Two New Human Cell Products To Accelerate Research and Drug Discovery for Neurodegenerative Disease content piece image
Product News

bit.bio Adds Two New Human Cell Products To Accelerate Research and Drug Discovery for Neurodegenerative Disease

Cell coding company bit.bio has announced an expansion to its product portfolio to enable scientists to study neurodegenerative diseases in a human context.
Combining Coding and Biology To Engineer Human Cells content piece image
Industry Insight

Combining Coding and Biology To Engineer Human Cells

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

Transformative Models for Research and Drug Discovery content piece image
Industry Insight

Transformative Models for Research and Drug Discovery

Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.
Advertisement